You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week: single protein identification method, Vibrio cholerae sequences from spotted filter paper, and more.
The firm said that its nucleic acid amplification test provides viral load measurements of HIV type 1 groups M/N and O, and HIV-2 within 70 minutes
The developer of assays to detect drug-resistant strains of HIV has now branched into Lassa detection, and will potentially be seeking instrument partners.
The test detects genomic drug resistance mutations in HIV-1 that can lead to treatment failure and is validated on the firm's automated Sentosa workflow.
Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.
Researchers profiled cervical microbe communities in relation to HPV, HIV, and cervical cytology status, identifying microbial shifts in high-grade lesions and HIV-positive cases.
OmniVis is developing the assay for cholera detection in environmental samples while the lab that created it is working toward a paper-based HIV test.
The assay's CE marking permits its use for the early diagnosis of HIV-1 in infants and for measuring viral load and disease progression using dried blood spot samples.
The assay, which uses the Bioneer ExiStation molecular diagnostics instrument, was also recently registered for purchase by the Global Fund.
The partners are planning to integrate the technology into Horizon's research tools and services and to develop it for applications in cell therapeutics.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.
In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.
According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.